Peringatan Keamanan

Systemic absorption of topical corticosteroids has produced reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Halcinonide

DB06786

small molecule approved investigational withdrawn

Deskripsi

Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide.

Struktur Molekul 2D

Berat 454.96
Wujud liquid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

157 Data
Trastuzumab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Halcinonide.
Tacrolimus Tacrolimus may increase the immunosuppressive activities of Halcinonide.
Phenylephrine The risk or severity of hypertension can be increased when Halcinonide is combined with Phenylephrine.
Aminoglutethimide The therapeutic efficacy of Halcinonide can be decreased when used in combination with Aminoglutethimide.
Insulin human The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin human.
Insulin lispro The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin lispro.
Insulin glargine The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin glargine.
Insulin pork The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin pork.
Troglitazone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Troglitazone.
Glimepiride The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Glimepiride.
Sulfisoxazole The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Sulfisoxazole.
Disopyramide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Disopyramide.
Acarbose The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Acarbose.
Metformin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Metformin.
Sulfadiazine The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Sulfadiazine.
Rosiglitazone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Rosiglitazone.
Acetohexamide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Acetohexamide.
Quinine The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Quinine.
Miglitol The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Miglitol.
Chlorpropamide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Chlorpropamide.
Nateglinide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Nateglinide.
Pentamidine The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Pentamidine.
Mifepristone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Mifepristone.
Tolazamide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Tolazamide.
Repaglinide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Repaglinide.
Phenformin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Phenformin.
Sulfamethoxazole The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Sulfamethoxazole.
Glyburide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Glyburide.
Glipizide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Glipizide.
Gliclazide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Gliclazide.
Tolbutamide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Tolbutamide.
Pioglitazone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Pioglitazone.
Bromocriptine The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Bromocriptine.
Gliquidone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Gliquidone.
Mitiglinide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Mitiglinide.
Sitagliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Sitagliptin.
Sunitinib The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Sunitinib.
Exenatide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Exenatide.
Mecasermin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Mecasermin.
Pramlintide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Pramlintide.
Glisoxepide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Glisoxepide.
Insulin aspart The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin aspart.
Insulin detemir The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin detemir.
Insulin glulisine The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin glulisine.
Glymidine The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Glymidine.
AICA ribonucleotide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with AICA ribonucleotide.
Buformin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Buformin.
Vildagliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Vildagliptin.
Voglibose The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Voglibose.
NN344 The risk or severity of hyperglycemia can be increased when Halcinonide is combined with NN344.
AMG-222 The risk or severity of hyperglycemia can be increased when Halcinonide is combined with AMG-222.
Bisegliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Bisegliptin.
Alogliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Alogliptin.
Dapagliflozin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Dapagliflozin.
Saxagliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Saxagliptin.
Liraglutide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Liraglutide.
Gosogliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Gosogliptin.
Linagliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Linagliptin.
Canagliflozin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Canagliflozin.
Glibornuride The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Glibornuride.
Benfluorex The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Benfluorex.
Empagliflozin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Empagliflozin.
Albiglutide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Albiglutide.
Dulaglutide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Dulaglutide.
Lobeglitazone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Lobeglitazone.
Netoglitazone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Netoglitazone.
Rivoglitazone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Rivoglitazone.
Ciglitazone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Ciglitazone.
Lixisenatide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Lixisenatide.
Insulin beef The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin beef.
Insulin degludec The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin degludec.
Insulin peglispro The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin tregopil.
Ipragliflozin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Ipragliflozin.
Dutogliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Dutogliptin.
Allicin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Allicin.
Tofogliflozin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Tofogliflozin.
Ertugliflozin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Ertugliflozin.
2,4-thiazolidinedione The risk or severity of hyperglycemia can be increased when Halcinonide is combined with 2,4-thiazolidinedione.
Teneligliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Teneligliptin.
Omarigliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Omarigliptin.
Carmegliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Carmegliptin.
Gemigliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Gemigliptin.
Anagliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Anagliptin.
Evogliptin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Evogliptin.
Sotagliflozin The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Sotagliflozin.
Balaglitazone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Balaglitazone.
Remogliflozin etabonate The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Remogliflozin etabonate.
Carbutamide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Carbutamide.
Guar gum The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Guar gum.
Metahexamide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Metahexamide.
Semaglutide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Semaglutide.
Taspoglutide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Taspoglutide.
Englitazone The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Englitazone.
Tirzepatide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Tirzepatide.
Gastric inhibitory polypeptide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Gastric inhibitory polypeptide.
Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Halcinonide.
Cyclosporine The risk or severity of adverse effects can be increased when Halcinonide is combined with Cyclosporine.
Digoxin The risk or severity of adverse effects can be increased when Halcinonide is combined with Digoxin.
Acetyldigitoxin The risk or severity of adverse effects can be increased when Halcinonide is combined with Acetyldigitoxin.

Target Protein

Steroid hormone receptor ERR1 ESRRA
Steroid hormone receptor ERR2 ESRRB
Estrogen-related receptor gamma ESRRG
Protein smoothened SMO

Referensi & Sumber

Synthesis reference: U.S. Patent 3,892,857.
Artikel (PubMed)
  • PMID: 25607913
    Draelos ZD: Demonstration of the biphasic release of 0.1% halcinonide cream. J Drugs Dermatol. 2015 Jan;14(1):89-90.
  • PMID: 3522448
    Ellis CN, Van Scott EJ: Clobetasol propionate cream versus halcinonide cream in psoriasis. Int J Dermatol. 1986 Jun;25(5):332-3.
  • PMID: 26658258
    Porcu G, Serone E, De Nardis V, Di Giandomenico D, Lucisano G, Scardapane M, Poma A, Ragnini-Wilson A: Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRgamma Receptor Activation. PLoS One. 2015 Dec 10;10(12):e0144550. doi: 10.1371/journal.pone.0144550. eCollection 2015.

Contoh Produk & Brand

Produk: 15 • International brands: 9
Produk
  • Halcinonide
    Cream • 1 mg/1g • Topical • US • Generic • Approved
  • Halcinonide
    Cream • 1 mg/1g • Topical • US • Generic • Approved
  • Halcinonide
    Cream • 1 mg/1g • Topical • US • Generic • Approved
  • Halcinonide Topical Solution
    Solution • 1 mg/1mL • Topical • US • Generic • Approved
  • Halog
    Cream • 1 mg/1g • Topical • US • Approved
  • Halog
    Solution • 1 mg/1mL • Topical • US • Approved
  • Halog
    Ointment • 1 mg/1g • Topical • US • Approved
  • Halog
    Cream • 1 mg/1g • Topical • US • Approved
Menampilkan 8 dari 15 produk.
International Brands
  • Adcortin — Daiichi Sankyo
  • Berodan — Dong Sung
  • Betacorton — Spirig
  • Confumin — Hwang's
  • Cortilate — Micro Gratia
  • Ha Le Te — Tianjin Pharmaceutical Group Xinzheng
  • Halciderm — Teofarma
  • Halcinonide-Pacific Pharm — Pacific
  • Sawastin — Sawai Seiyaku

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul